Kymera Therapeutics

Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kymera Therapeutics reports successful 2022, eyes growth through strategic partnerships

Kymera Therapeutics had a successful year, with promising data in multiple programs and a focus on targeted protein degradation.
The company's financial position is strong, with key goals set for 2023, including collaborations and advancing pipeline programs.
Challenges lie in program prioritization, mechanism of action clarity, and optimizing dosing strategies, while opportunities exist in partnerships and therapeutic innovation.
Overall, Kymera's innovative approach and strategic outlook position it well for growth and continued success in 2023.

Kymera Therapeutics reports solid Q1 performance and eyes clinical milestones

Kymera Therapeutics is progressing well in its pipeline development, focusing on innovative programs with broad enrollment criteria.
Financially, the company is stable with a strong cash position and a clear runway into the future.
While facing challenges in capital allocation and program development, Kymera is actively seeking opportunities for growth and collaboration.

Kymera Therapeutics reports robust earnings, advances in clinical trials

Kymera Therapeutics showcased strong financial performance, progress in clinical trials, and a patient-centric approach to drug development.
While facing challenges in clarity on certain trial aspects and partnership limitations, the company is well-positioned for growth and innovation.
Opportunities lie in expanding clinical studies, developing new INDs, and exploring additional indications for their drug portfolio.

Kymera Therapeutics achieves clinical milestones and financial stability for growth

Kymera Therapeutics has made significant progress in clinical development and financial stability, positioning the company for future growth and success.
The company's focus on genetically validated targets, degrader mechanisms, and combination therapies underscores a strategic and innovative approach to drug development.
While facing challenges in dose optimization and safety standards, Kymera has opportunities to leverage its strengths in solid tumors and immunology for therapeutic advancements.
Overall, Kymera's performance, strengths, and opportunities outweigh the challenges, indicating a promising outlook for the company's future in the biopharmaceutical industry.

Kymera Therapeutics reports robust earnings, advances oral immunology pipeline

Kymera Therapeutics is in a strong financial position with a clear runway for growth, focusing on advancing their oral immunology pipeline and strategic partnerships. They face challenges in prioritizing indications but have opportunities for collaborations and innovative therapeutic development.
The company's progress in clinical programs, including dose escalation trials and milestone achievements, reflects their commitment to advancing novel therapies and addressing unmet medical needs in inflammatory diseases, oncology, and immunology.

Kymera Therapeutics reports solid Q1 performance and eyes program expansion

Kymera Therapeutics had a strong start in 2024 with promising program updates and financial stability.
The company's focus on innovative degrader medicines and potential indication expansion positions it for future growth.
Challenges in data disclosure timing and partnership decisions require strategic navigation for sustained success.
Overall, Kymera's performance, strengths, and opportunities indicate a positive trajectory with key milestones ahead.

Kymera Therapeutics reports strong Q2 earnings and eyes CNS expansion

Kymera Therapeutics showcased strong financial performance, progress in clinical trials, and a focus on innovative drug development approaches.
While facing challenges in market competition and financial management, the company is well-positioned to capitalize on growth opportunities.
Overall, Kymera's emphasis on developing effective oral immunology drugs and exploring CNS indications sets a positive trajectory for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Cutaneous T-Cell Lymphoma is the second orphan drug designation for KT-333 Cutaneous T-Cell Lymphoma is the second orphan drug designation for KT-333

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma

WATERTOWN, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced that Nello Mainolfi, PhD, Co-Founder, President and CEO, will participate in Fireside Chats at the following upcoming investor conferences:

Kymera Therapeutics to Participate in Upcoming September Conferences

Ecolab

Six Flags

Although US stocks closed mostly lower on Tuesday, there were a few notable insider trades.

Insiders Buying Ecolab, Kymera Therapeutics And This Consumer Cyclical Stock

WATERTOWN, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 2,769,228 shares of its common stock (“Common Stock”) at a price of $26.00 per share and pre-funded warrants (“Pre-Funded Warrants”) to purchase up to an aggregate of 3,000,000 shares of Common Stock at a purchase price of $25.9999 per pre-funded warrant share, through a private investment in public equity (“PIPE”) financing. The Pre-Funded Warrants will have an exercise price of $0.0001 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. Kymera anticipates the gross proceeds from the PIPE to be approximately $150.0 million, before deducting offering expenses. The financing is expected to close on August 22, 2022, subject to customary closing conditions. Proceeds from the financing will support Kymera's ongoing research and development activities as well as general corporate purposes and working capital.

Kymera Announces $150 Million Private Placement Equity Financing

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Nello Mainolfi - Founder & CEO Jared Gollob - Chief Medical Officer Bruce Jacobs - CFO Conference Call Participants Bradley Canino - Stifel Michael Schmidt - Guggenheim Chris Shibutani - Goldman Sachs Richard Law - Credit Suisse Vikram Purohit - Morgan Stanley Marc Frahm - Cowen Zhiqiang Shu - Berenberg Eliana Merle - UBS Kalpit Patel - B. Riley Eric Joseph - JPMorgan Operator Welcome to the Kymera Therapeutics Quarterly Conference Call.

Kymera Therapeutics, Inc. (KYMR) CEO Nello Mainolfi on Q2 2022 Results - Earnings Call Transcript

Initiated dosing in patient cohort (Part C) of IRAK4 degrader KT-474 Phase 1 trial, on track for data by year end

Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update

Kymera Therapeutics, Inc. (KYMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Kymera Therapeutics, Inc. (KYMR) to Report a Decline in Earnings: What to Look Out for

WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report second quarter 2022 financial results on August 9, 2022 and will host a conference call at 8:30 a.m. ET that day.

Kymera Therapeutics to Report Second Quarter 2022 Results on August 9

WATERTOWN, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Leigh Morgan to its Board of Directors. Ms. Morgan joins Kymera's Board as a senior executive accomplished in scaling global, profitable, high-performing organizations.

Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan

KT-333 is a first-in-class heterobifunctional degrader of the transcriptional regulator STAT3 in development for T cell malignancies and solid tumors KT-413 is a first-in-class degrader of IRAK4 and the IMiD substrates Ikaros and Aiolos in development for MYD88-mutant B cell lymphomas  Initial safety and proof-of-mechanism clinical data for both programs to be shared in second half of 2022 WATERTOWN, Mass. , June 15, 2022 /PRNewswire/ -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, has recently dosed the first patients in separate Phase 1 clinical trials evaluating the STAT3 degrader KT-333 and the IRAKIMiD degrader KT-413.

Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413

WATERTOWN, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KT-333 for the treatment of Peripheral T-cell Lymphoma (PTCL). KT-333 is a first-in-class degrader of the transcriptional regulator STAT3. STAT3 activation has been shown to be a key modulator of disease in PTCL, and there are currently no approved therapies for PTCL that target this pathway.

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell Lymphoma

WATERTOWN, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will present new preclinical data demonstrating that STAT3 degradation blocked Th17 development and cytokine release and prevented collagen-induced arthritis (CIA), a pre-clinical model of rheumatoid arthritis, today at the EULAR 2022 Congress in Copenhagen, Denmark.

Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid Arthritis

Kezar Life Sciences Inc

Protagonist Therapeutics

It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. The post 3 Biotech Stocks to Buy Before They Boom appeared first on InvestorPlace.

3 Biotech Stocks to Buy Before They Boom

WATERTOWN, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, presented data demonstrating that the clinical stage selective IRAK4 degrader KT-474 degrades IRAK4 and inhibits cytokine production in different immune and skin cell types at the Society of Investigative Dermatology (SID) Annual Meeting 2022, taking place from May 18 - 21, 2022 in Portland, Oregon.

Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting

-Data to be shared at the American Association of Immunologists (AAI) Annual Meeting

Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2022 Results Conference Call May 3, 2022 8:00 AM ET Company Participants Nello Mainolfi - Founder and Chief Executive Officer Jared Gollob - Chief Medical Officer Bruce Jacobs - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Brad Canino - Stifel Paul Jeng - Guggenheim Gospel Enyindah-Asonye - Morgan Stanley Kalpit Patel - B. Riley Divya Rao - Cowen and Company Eric Joseph - JPMorgan Zhiqiang Shu - Berenberg Operator Welcome to Kymera Therapeutics Quarterly Conference Call.

Kymera Therapeutics, Inc. (KYMR) CEO Nello Mainolfi on Q1 2022 Results - Earnings Call Transcript

In its Q1 earnings release, Kymera Therapeutics Inc (NASDAQ: KYMR) announced the selection of the equivalent of 100 mg, in the fed state, as the dose for the Phase 1 patient cohort (Part C). The cohort is expected to enroll up to 20 patients with hidradenitis suppurativa (HS) and atopic.

Why Kymera Therapeutics Shares Are Falling Today

The biotech upset investors today with disappointing news for its lead program.

Why Kymera Therapeutics Stock Is Getting Hammered Today

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.97% and 44.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Lags Revenue Estimates

IRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days,  enabling inclusion of exploratory clinical efficacy endpoints and extended safety monitoring

Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update

Company to begin hosting quarterly calls to provide broad updates across pipeline Company to begin hosting quarterly calls to provide broad updates across pipeline

Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences

MDM2 degradation demonstrated differentiated biological activity and superior cell killing compared to small molecule inhibition in p53 wild-type tumors and led to tumor regressions in xenograft models of ALL and AML

Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Lags Revenue Estimates

Completed dose escalation in the KT-474 SAD and MAD portions of Phase 1 trial, with near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of multiple disease-relevant cytokines and favorable safety profile. HS and AD patient cohort data expected in 2H22

Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update

Arvinas Inc

Pfizer

Is it time to buy a basket of biotech stocks?

News for Kymera Therapeutics Stock (KYMR)